Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qiwei Baizhu San (QWBS) is a classic Traditional Chinese Medicine (TCM) formula traditionally used to treat gastrointestinal disorders associated with spleen deficiency, such as chronic diarrhea and dyspepsia. The formula typically consists of seven herbal components: *Atractylodes macrocephala* (Baizhu), *Panax ginseng* (Renshen) or *Codonopsis pilosula* (Dangshen), *Poria cocos* (Fuling), *Glycyrrhiza uralensis* (Gancao), *Pogostemon cablin* (Guanghuoxiang), *Pueraria lobata* (Gegen), and *Saussurea costus* (Muxiang). Modern clinical research, including studies conducted by Wuxi Hospital of Chinese Medicine, has expanded its application to metabolic diseases such as obesity and type 2 diabetes. It is hypothesized to work by modulating the gut microbiota, improving intestinal barrier function, and regulating glucose and lipid metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qiwei baizhu san.